Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25B | P30305 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.48 |
| ▸ | GAA | P10253 | 9/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | HPGD | P15428 | 4/20 | 0.48 |
| ▸ | PKM | P14618 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | THRB | P10828 | 3/20 | 0.47 |
| ▸ | GFER | P55789 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | PLEC | Q15149 | 1/20 | 0.47 |
| ▸ | NEU3 | Q9UQ49 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9195326 | 0.85 | CDC25B (0.73) | CDC25BKDM4EGAAALDH1A1HPGD | |
| SCHEMBL9177276 | 0.83 | CDC25B (0.59) | CDC25BKDM4EGAAALDH1A1HPGD | |
| SCHEMBL8075701 | 0.83 | CDC25B (0.59) | CDC25BKDM4EGAAALDH1A1HPGD | |
| SCHEMBL29870405 | 0.83 | CDC25B (0.59) | CDC25BKDM4EGAAALDH1A1HPGD | |
| SCHEMBL5405584 | 0.82 | CDC25B (0.53) | CDC25BKDM4EGAAPKMMAPT | |
| SCHEMBL8441914 | 0.82 | CDC25B (0.54) | CDC25BKDM4EGAAALDH1A1HPGD | |
| SCHEMBL9500692 | 0.82 | CDC25B (0.54) | CDC25BKDM4EGAAALDH1A1HPGD | |
| SCHEMBL9436677 | 0.81 | KDM4E (0.67) | KDM4EGAAALDH1A1HPGDPKM | |
| SCHEMBL2590708 | 0.79 | L3MBTL1 (0.53) | CDC25BALDH1A1PKMNEU3HSD17B10 | |
| SCHEMBL31325736 | 0.78 | HTT (0.47) | CDC25BKDM4EGAAPKMMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040116399-A1 | Inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. | 2004-06-17 | — | — | US | disclosed |
| US-6720317-B1 | 1-NAPHTH-2-YL-1H-PYRAZOLE-5-(4-AMIDINOPHENYL)CARBOXYAMIDE, MULTIPLY SUBSTITUTED; NON AMIDINO ANTICOAGULANTS; HEMOSTATIC AGENTS | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-13 | — | — | US | disclosed |
| US-6686368-B1 | Inhibitors of factor Xa | MILLENNIUM PAHRMACEUTICALS, INC. | 2004-02-03 | — | — | US | disclosed |
| US-6632815-B2 | Show selectivity for factor Xa versus other proteases of coagulation or the fibrinolytic cascades | MILLENNIUM PHARMACEUTICALS, INC. | 2003-10-14 | — | — | US | disclosed |
| EP-0931070-B1 | HETAROYL CYCLOHEXANEDIONE DERIVATIVES WITH HERBICIDAL EFFECT | BASF AG (DE) | 2003-03-19 | — | — | EP | disclosed |
| US-6479436-B1 | SUCH AS 2-(8-BROMOQUINOLIN-5-YL)CARBONYL-1,3-CYCLOHEXANEDIONE | BASF AKTIENGESELLSCHAFT (DE) | 2002-11-12 | — | — | US | disclosed |
| US-20020091116-A1 | Show selectivity for factor Xa versus other proteases of coagulation or the fibrinolytic cascades | MILLENNIUM PHARMACEUTICALS, INC. | 2002-07-11 | — | — | US | disclosed |
| EP-1216231-A2 | INHIBITORS OF FACTOR Xa | Millennium Pharmaceuticals, Inc. (US) | 2002-06-26 | — | — | EP | disclosed |
| US-6262074-B1 | 4-Hetaroylpyrazol derivatives and the use thereof as herbicides | BASF AKTIENGESELLSCHAFT (DE) | 2001-07-17 | — | — | US | disclosed |
| WO-2001019798-A2 | INHIBITORS OF FACTOR Xa | COR THERAPEUTICS INC. (US) | 2001-03-22 | — | — | WO | disclosed |
| EP-0929546-A1 | 4-HETAROYLPYRAZOL DERIVATIVES AND THE USE THEREOF AS HERBICIDES | BASF AKTIENGESELLSCHAFT (DE) | 1999-07-21 | — | — | EP | disclosed |
| WO-1998012192-A1 | 4-HETAROYLPYRAZOL DERIVATIVES AND THE USE THEREOF AS HERBICIDES | BASF AKTIENGESELLSCHAFT (DE) | 1998-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020091116-A1 | Show selectivity for factor Xa versus other proteases of coagulation or the fibrinolytic cascades | SERPINC1, TFPI, F2 | CDC25B 3701/4885KDM4E 3940/4885GAA 402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.